Harrow Health Stock Price, News & Analysis (NASDAQ:HROW) $9.06 -0.04 (-0.44%) (As of 02:27 PM ET) Add Compare Share Share Today's Range$8.72▼$9.0650-Day Range$8.10▼$16.3652-Week Range$7.60▼$28.25Volume251,085 shsAverage Volume520,237 shsMarket Capitalization$318.19 millionP/E RatioN/ADividend YieldN/APrice Target$38.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Harrow Health MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside330.6% Upside$38.80 Price TargetShort InterestBearish17.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 2 Articles This WeekInsider TradingAcquiring Shares$266,174 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.43) to $0.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector594th out of 935 stocksPharmaceutical Preparations Industry279th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingHarrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.80, Harrow Health has a forecasted upside of 330.6% from its current price of $9.01.Amount of Analyst CoverageHarrow Health has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.40% of the outstanding shares of Harrow Health have been sold short.Short Interest Ratio / Days to CoverHarrow Health has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Harrow Health has recently decreased by 2.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHarrow Health does not currently pay a dividend.Dividend GrowthHarrow Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 2.6 News and Social Media Coverage News SentimentHarrow Health has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Harrow Health this week, compared to 2 articles on an average week.Search Interest6 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows5 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $266,174.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.60% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.75% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow Health are expected to grow in the coming year, from ($0.43) to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow Health is -20.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow Health is -20.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow Health has a P/B Ratio of 8.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harrow Health Stock (NASDAQ:HROW)Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesNovember 24, 2023 | seekingalpha.comHROWM Harrow Health, Inc. NT CAL 27November 20, 2023 | finance.yahoo.comHarrow to Present at Two Investor Conferences in NovemberNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 17, 2023 | benzinga.comHarrow Recent Insider ActivityNovember 14, 2023 | msn.comHarrow Health (NASDAQ:HROW) Plummets on Dismal Q3 PrintNovember 14, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Harrow Health (HROW), Synlogic (SYBX)November 14, 2023 | markets.businessinsider.comWhy Is Eyecare-Focused Harrow Health Stock Trading Lower Today?November 14, 2023 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call TranscriptNovember 28, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 13, 2023 | finance.yahoo.comHarrow Announces Third Quarter 2023 Financial ResultsNovember 5, 2023 | morningstar.comHarrow Inc HROWOctober 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Guardant Health (GH), TELA Bio (TELA) and Harrow Health (HROW)October 24, 2023 | finance.yahoo.comHarrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.October 18, 2023 | seekingalpha.comImplications Of Harrow's Short-Term GuidanceSeptember 29, 2023 | finance.yahoo.comHarrow Health, Inc. Changes Corporate Name to Harrow, Inc.September 27, 2023 | seekingalpha.comHarrow Health's 5-Year GuidanceSeptember 26, 2023 | finance.yahoo.comMelt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural SedationSeptember 21, 2023 | benzinga.comHarrow Health 10% Owner Trades $292K In Company StockAugust 11, 2023 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call TranscriptAugust 10, 2023 | seekingalpha.comHarrow Health, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 3, 2023 | fool.comHarrow Health (NASDAQ: HROW)August 1, 2023 | seekingalpha.comHarrow Health And Its Interesting 11.6% 2027 Baby BondJuly 26, 2023 | bizjournals.comHarrow Health inks deals for the rights to eight medicationsJuly 19, 2023 | markets.businessinsider.comWhy Harrow Health Stock Is Trading Higher Today?July 19, 2023 | finance.yahoo.comWhy Shares of Harrow Health Are Jumping WednesdayJuly 19, 2023 | msn.comHarrow prices $60 million stock offering, sees Q2 revenue in excess of $31M above consensusJuly 19, 2023 | msn.comHarrow acquires US and Canadian commercial rights for Santen’s Ophthalmic productsSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$38.80 High Stock Price Target$45.00 Low Stock Price Target$34.40 Potential Upside/Downside+326.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,090,000.00 Net Margins-12.44% Pretax Margin-11.36% Return on Equity-6.55% Return on Assets-1.08% Debt Debt-to-Equity Ratio2.42 Current Ratio5.80 Quick Ratio5.33 Sales & Book Value Annual Sales$88.60 million Price / Sales3.61 Cash Flow$0.21 per share Price / Cash Flow42.42 Book Value$1.01 per share Price / Book9.01Miscellaneous Outstanding Shares35,120,000Free Float30,342,000Market Cap$319.59 million OptionableOptionable Beta0.48 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsMarinus PharmaceuticalsNASDAQ:MRNSSilence TherapeuticsNASDAQ:SLNuniQureNASDAQ:QURENature's Sunshine ProductsNASDAQ:NATRErascaNASDAQ:ERASView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 202,892 shares on 11/24/2023Ownership: 0.038%Mark L BaumBought 7,500 shares on 11/16/2023Total: $60,825.00 ($8.11/share)Morgan StanleyBought 8,364 shares on 11/16/2023Ownership: 5.062%Westside Investment Management Inc.Bought 25,275 shares on 11/16/2023Ownership: 0.453%Stansberry Asset Management LLCBought 12,293 shares on 11/15/2023Ownership: 0.397%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions Should I buy or sell Harrow Health stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow Health's stock price target for 2024? 2 brokers have issued 1-year target prices for Harrow Health's stock. Their HROW share price targets range from $34.40 to $45.00. On average, they predict the company's share price to reach $38.80 in the next year. This suggests a possible upside of 330.2% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2023? Harrow Health's stock was trading at $14.76 at the beginning of the year. Since then, HROW shares have decreased by 38.9% and is now trading at $9.02. View the best growth stocks for 2023 here. When is Harrow Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HROW earnings forecast. How were Harrow Health's earnings last quarter? Harrow Health, Inc. (NASDAQ:HROW) posted its earnings results on Monday, November, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.12. The company earned $34.27 million during the quarter, compared to analyst estimates of $37.58 million. Harrow Health had a negative net margin of 12.44% and a negative trailing twelve-month return on equity of 6.55%. The business's quarterly revenue was up 50.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) EPS. What ETFs hold Harrow Health's stock? ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Harrow Health issued on next quarter's earnings? Harrow Health issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $129.00 million-$136.00 million, compared to the consensus revenue estimate of $141.53 million. What other stocks do shareholders of Harrow Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). Who are Harrow Health's major shareholders? Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (5.15%), Morgan Stanley (5.06%), Private Capital Management LLC (4.04%), Invictus Private Wealth LLC (1.14%), Paradigm Capital Management Inc. NY (1.12%) and Stifel Financial Corp (0.97%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow Health? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:HROW) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.